Serabelisib Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Serabelisib Growth

• Precision medicine approach targeting PIK3CA-driven diseases

Serabelisib is a highly selective oral PI3Kα inhibitor designed to inhibit the PI3K/AKT/mTOR signaling pathway while minimizing the off-target toxicities associated with pan-PI3K inhibitors. Activating PIK3CA mutations are among the most common oncogenic alterations, occurring in approximately 30-40% of hormone receptor-positive breast cancers and in numerous overgrowth syndromes. This biomarker-driven strategy enables treatment of well-defined patient populations and supports broader commercial potential across oncology and rare genetic disorders.

• Clinical validation in rare overgrowth syndromes

Serabelisib has demonstrated encouraging activity in patients with PIK3CA-related overgrowth spectrum (PROS) and other PI3K pathway disorders. Published clinical studies have shown reductions in tissue overgrowth, improvements in pain, and enhanced physical function with a manageable safety profile. As these disorders have limited treatment options, positive efficacy data support continued development and potential uptake in rare disease markets where premium pricing and long treatment durations are common. Peer-reviewed publications have highlighted sustained clinical benefit with selective PI3Kα inhibition in genetically confirmed patients.

• Differentiated safety profile enables combination therapy

Compared with earlier pan-PI3K inhibitors, Serabelisib's selective inhibition of the PI3Kα isoform has demonstrated improved tolerability, facilitating combination with endocrine therapies, targeted agents, and other pathway inhibitors. The molecule is also being incorporated into the PIKTOR platform, which combines Serabelisib with the dual mTORC1/2 inhibitor sapanisertib to achieve more comprehensive inhibition of the PI3K/AKT/mTOR pathway while addressing resistance mechanisms. This strategy could broaden its applicability across multiple solid tumors.

• Large commercial opportunity across multiple tumor types

The PI3K/AKT/mTOR pathway is one of the most frequently dysregulated signaling pathways in cancer. Because aberrant PI3K signaling contributes not only to primary oncogenic drivers but also to acquired resistance against endocrine therapy, HER2-targeted therapy, and other targeted treatments, Serabelisib has potential utility across several solid tumors. The opportunity to combine with standard-of-care regimens expands the addressable patient population beyond rare diseases alone.

• Potential expansion through biomarker-guided development

Advances in next-generation sequencing and routine molecular profiling are increasing identification of PIK3CA-mutated patients, improving patient selection for PI3K-targeted therapies. As precision oncology adoption continues globally, Serabelisib could benefit from expanding genomic testing infrastructure and greater physician familiarity with biomarker-directed treatment strategies, potentially improving clinical adoption following successful regulatory approvals.

• Commercial outlook and sales potential

No company-sponsored revenue guidance or verified analyst consensus sales forecasts have been published for Serabelisib. Consequently, assigning specific sales projections would be speculative. Its long-term commercial potential will depend on successful late-stage clinical development, regulatory approvals, differentiation from approved PI3K inhibitors such as alpelisib, and expansion into multiple biomarker-defined indications. If these milestones are achieved, Serabelisib could establish a meaningful position within the precision oncology and rare disease markets.

Serabelisib Recent Developments

In March 2026, Sensei Biotherapeutics acquired Serabelisib through its corporate transaction with Faeth Therapeutics. Sensei currently drives the clinical pipeline and commercialization strategy for the compound, maintaining rights to assume full development responsibilities.

“Serabelisib Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Serabelisib for potential indication like Vascular malformations in the 7MM. A detailed picture of Serabelisib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Serabelisib for potential indications. The Serabelisib market report provides insights about Serabelisib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Serabelisib performance, future market assessments inclusive of the Serabelisib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Serabelisib sales forecasts, along with factors driving its market.

Serabelisib Drug Summary

Serabelisib (formerly TAK-117 or MLN1117) is an investigational, orally administered, selective phosphoinositide 3-kinase alpha (PI3Kα) inhibitor being developed for the treatment of disorders driven by aberrant PI3K signaling, including PIK3CA-related overgrowth spectrum (PROS) and other rare genetic diseases. By selectively inhibiting the PI3Kα isoform encoded by the PIK3CA gene, serabelisib aims to reduce pathological cell growth, vascular malformations, and tissue overgrowth while minimizing the off-target toxicities associated with broader PI3K inhibition. Clinical studies have demonstrated pharmacodynamic activity and a generally manageable safety profile, with hyperglycemia, gastrointestinal events, and rash among the commonly observed adverse events. The drug has received orphan drug designation for PIK3CA-related overgrowth spectrum in multiple regions and continues to be evaluated in clinical trials to determine its long-term efficacy and safety as a targeted therapy for patients with rare overgrowth syndromes caused by activating PIK3CA mutations. The report provides Serabelisib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Serabelisib Market Report

The report provides insights into:

• A comprehensive product overview including the Serabelisib MoA, description, dosage and administration, research and development activities in potential indication like Vascular malformations.
• Elaborated details on Serabelisib regulatory milestones and other development activities have been provided in Serabelisib market report.
• The report also highlights Serabelisib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Serabelisib market report also covers the patents information, generic entry and impact on cost cut.
• The Serabelisib market report contains current and forecasted Serabelisib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Serabelisib market report also features the SWOT analysis with analyst views for Serabelisib in potential indications.

Methodology

The Serabelisib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Serabelisib Analytical Perspective

• In-depth Serabelisib Market Assessment

This Serabelisib sales market forecast report provides a detailed market assessment of Serabelisib for potential indication like Vascular malformations in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Serabelisib sales data uptil 2034.

• Serabelisib Clinical Assessment

The Serabelisib market report provides the clinical trials information of Serabelisib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Serabelisib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Serabelisib Market Potential & Revenue Forecast

• Projected market size for the Serabelisib and its key indications
• Estimated Serabelisib sales potential (Serabelisib peak sales forecasts)
• Serabelisib Pricing strategies and reimbursement landscape

Serabelisib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Serabelisib Market positioning compared to existing treatments
• Serabelisib Strengths & weaknesses relative to competitors

Serabelisib Regulatory & Commercial Milestones

• Serabelisib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Serabelisib Clinical Differentiation

• Serabelisib Efficacy & safety advantages over existing drugs
• Serabelisib Unique selling points

Serabelisib Market Report Highlights

• In the coming years, the Serabelisib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Serabelisib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Serabelisib’s dominance.
• Other emerging products for Vascular malformations are expected to give tough market competition to Serabelisib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Serabelisib in potential indications.
• Analyse Serabelisib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Serabelisib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Serabelisib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Serabelisib? How strong is Serabelisib’s clinical and commercial performance?
• What is Serabelisib’s clinical trial status in each individual indications such as Vascular malformations and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Serabelisib Manufacturers?
• What are the key designations that have been granted to Serabelisib for potential indications? How are they going to impact Serabelisib’s penetration in various geographies?
• What is the current and forecasted Serabelisib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Serabelisib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Serabelisib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Serabelisib? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.